---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-24-001514"
form_type: "8-K"
ticker: "INKT"
cik: "0001840229"
company_name: "MiNK Therapeutics, Inc."
filed_at: "2024-03-21T23:59:59+00:00"
generated_at: "2026-06-04T10:24:17.960905+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# MiNK Therapeutics reports FY2023 net loss $22.5M; cash $3.4M at year-end

## Summary
- Net loss for 2023 was $22.5M ($0.65/share) vs. $28.0M ($0.83/share) in 2022.
- Cash and cash equivalents $3.4M at Dec 31, 2023; received $5M post-year-end from Agenus convertible note.
- Launched Phase 2 trial of agenT-797 with botensilimab/balstilimab/chemo in 2L gastroesophageal cancers.
- Entered collaboration with Immunoscape to develop TCR-based therapies against novel targets.
- Nature Communications publication showed >70% survival in ARDS patients on mechanical ventilation with agenT-797.

## SEC filing metadata
- accession: 0001171843-24-001514
- form_type: 8-K
- ticker: INKT
- cik: 0001840229
- company_name: MiNK Therapeutics, Inc.
- filed_at: 2024-03-21T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1840229/000117184324001514/0001171843-24-001514-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1840229/000117184324001514/f8k_032124.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-24-001514
- JSON: https://secwatch.observer/filing/0001171843-24-001514.json
- Plain text: https://secwatch.observer/filing/0001171843-24-001514.txt

## Key facts
- Earnings Releases
  MiNK Therapeutics, Inc. reported fourth quarter and full-year 2023 results: net income Net loss for the year ended December 31, 2023 was $22.5 million, or $0.65 per share, EPS $0.65.
  - Period: fourth quarter and full-year 2023
  - Net income: Net loss for the year ended December 31, 2023 was $22.5 million, or $0.65 per share
  - EPS: $0.65
  - Result: reported results
  source text: MiNK Therapeutics, Inc. announced its financial results for the quarter and year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1840229/000117184324001514/0001171843-24-001514-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.